A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: Enfortumab vedotin plus pembrolizumab Review
| Authors: | Hoimes, C. J.; Flaig, T. W.; Milowsky, M. I.; Friedlander, T. W.; Bilen, M. A.; Gupta, S.; Srinivas, S.; Merchan, J. R.; McKay, R. R.; Petrylak, D. P.; Sasse, C.; Moreno, B. H.; Yu, Y.; Carret, A. S.; Rosenberg, J. E. |
| Review Title: | A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: Enfortumab vedotin plus pembrolizumab |
| Abstract: | WHAT IS THIS SUMMARY ABOUT?: This summary provides the results of a study of two treatments for cancer, enfortumab vedotin and pembrolizumab, that were studied together against locally advanced or metastatic urothelial cancer (la/mUC), a cancer that occurs most commonly in the bladder. WHAT WERE THE RESULTS?: In the 45 patients studied, around 16% did have serious side effects, but most side effects were manageable. Twenty-four percent of patients, however, stopped the study treatment because of their side effects. Within about 2 months of starting treatment, most patients' (73%) tumors were smaller and stayed smaller, on average, for more than 2 years. WHAT DO THE RESULTS MEAN?: The combination of enfortumab vedotin plus pembrolizumab is a new treatment option for patients with locally advanced or metastatic urothelial cancer when they cannot receive the typical treatment, cisplatin. Advanced or metastatic urothelial cancer is a type of cancer where the cancer has already spread outside of the bladder or urinary tract. |
| Keywords: | pathology; bladder tumor; urinary bladder neoplasms; monoclonal antibody; urologic neoplasms; antibodies, monoclonal; carcinoma, transitional cell; transitional cell carcinoma; urothelial cancer; urinary tract tumor; antibodies, monoclonal, humanized; humans; human; pembrolizumab; enfortumab vedotin; lay summary; plain language summary |
| Journal Title: | Future Oncology |
| Volume: | 20 |
| Issue: | 7 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2024-03-01 |
| Start Page: | 351 |
| End Page: | 360 |
| Language: | English |
| DOI: | 10.2217/fon-2023-0112 |
| PUBMED: | 37994649 |
| PROVIDER: | scopus |
| PMCID: | PMC10988537 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
